Stephen Thorne

Company: KaliVir Immunotherapeutics

Job title: Chief Scientific Officer

Seminars:

VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery 2:30 pm

• KaliVir has developed the VET platform to develop oncolytic virus backbones capable of achieving systemic delivery to solid tumors • VET3-TGI represents the lead internal product from this platform and is undergoing clinical translational development • In addition to unique intravenous delivery capabilities, VET3-TGI targets TGF-beta within the tumor microenvironment • Pre-clinical data with…Read more

day: Day One